| 06/26/20 | HRTX | HTX-011 (Resubmitted NDA) | FDA decision on HTX-011 for the management of postoperative pain |
| 06/26/20 | ICPT | Obeticholic acid (NDA) | FDA decision on obeticholic acid for fibrosis due to nonalcoholic steatohepatitis |
| 06/25/20 | ZGNX | FINTEPLA (NDA) | FDA decision on FINTEPLA for the treatment of seizures associated with Dravet syndrome |
| 06/23/20 | TKPHF.PK, TAK | ALUNBRIG (NDA) | FDA decision on ALUNBRIG as first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC |
| 06/19/20 | GSK.L, GSK | Belantamab mafodotin (BLA) | FDA decision on Belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma |
| 06/19/20 | EVOK | GimotI (NDA resubmission) | FDA decision on Gimoti for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. |